Gerresheimer (ETR:GXI) received a €59.60 ($69.30) price objective from equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 10.98% from the company’s current price.
Other research analysts also recently issued reports about the company. Credit Suisse Group set a €87.00 ($101.16) price target on Gerresheimer and gave the company a “buy” rating in a report on Tuesday, October 15th. Berenberg Bank set a €81.00 ($94.19) target price on Gerresheimer and gave the stock a “buy” rating in a research note on Wednesday, November 20th. Hauck & Aufhaeuser set a €50.00 ($58.14) target price on Gerresheimer and gave the stock a “sell” rating in a research note on Tuesday, December 17th. Deutsche Bank set a €80.00 ($93.02) target price on Gerresheimer and gave the stock a “buy” rating in a research note on Wednesday, November 20th. Finally, Goldman Sachs Group set a €65.00 ($75.58) target price on Gerresheimer and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of €70.96 ($82.51).
Shares of GXI stock traded up €0.80 ($0.93) on Monday, reaching €66.95 ($77.85). 25,317 shares of the company’s stock were exchanged, compared to its average volume of 140,925. The company’s fifty day simple moving average is €66.89 and its 200 day simple moving average is €68.23. The stock has a market capitalization of $2.09 billion and a PE ratio of 10.15. Gerresheimer has a 52 week low of €56.50 ($65.70) and a 52 week high of €74.80 ($86.98). The company has a current ratio of 0.81, a quick ratio of 0.54 and a debt-to-equity ratio of 65.99.
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Recommended Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.